Loading...
Docoh

Phio Pharmaceuticals (PHIO)

Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities.

PHIO stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Aug 22
29 Sep 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 18.07M 18.07M 18.07M 18.07M 18.07M 18.07M
Cash burn (monthly) 813K 950.42K 840.33K 1.03M 809.67K 936.25K
Cash used (since last report) 2.43M 2.85M 2.52M 3.08M 2.42M 2.8M
Cash remaining 15.64M 15.22M 15.55M 14.99M 15.65M 15.27M
Runway (months of cash) 19.2 16.0 18.5 14.6 19.3 16.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Aug 22 Patricia A Bradford Common stock, $0.0001 par value Grant Acquire A No No 0 20,000 0 20,000
1 Mar 22 Gerrit Dispersyn Common stock, $0.0001 par value Payment of exercise Dispose F No No 0.821 8,954 7.35K 212,327
1 Mar 22 Caitlin Kontulis Common stock, $0.0001 par value Payment of exercise Dispose F No No 0.821 4,011 3.29K 103,815
15 Feb 22 Robert J Bitterman Common stock, $0.0001 par value Grant Acquire A No No 0 10,000 0 25,826
13F holders Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Largest transactions Shares Bought/sold Change

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abandon, attain, boosting, central, CEO, chain, commodity, confidence, consumer, costly, departure, deteriorate, deterioration, distant, domestic, downturn, elevated, exhaustion, extreme, foregoing, fourth, geopolitical, higher, inflation, inflationary, labor, manipulation, million, monetary, overhead, play, preserving, prolonged, quality, recession, Reserve, reversing, role, stability, strategy, Summary, survive, transportation, unable, unpredictable, unstable, unvested, widely
Removed: accrual, achievement, applying, approval, approximate, assessed, asset, award, Basic, behavior, billed, calculate, charged, Chief, classification, collateral, commencement, comprehensive, computed, confer, consist, cumulative, deposit, determinable, Diluted, dividing, forfeiture, greater, initial, input, Institutet, issue, Karolinska, measured, obtained, passage, payable, payment, prepaid, readily, recognition, representing, revalued, revise, stockholder, subsequent, superior, Sweden, turnover, ultimately, underlying, vest